-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QkvLpEqgp10J59px1KPqHclamoxkCZVS2brKQql7scHucclHuuZxpw85lGkWpHMO
 DPZkBBgCvsddFh8PHiQtOg==

<SEC-DOCUMENT>0000950123-08-005055.txt : 20080825
<SEC-HEADER>0000950123-08-005055.hdr.sgml : 20080825
<ACCEPTANCE-DATETIME>20080502141806
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-08-005055
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20080502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>LETTER TO THE SEC</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="y57292cry5729201.gif" alt="(NOVOGEN LOGO)">
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">May&nbsp;2, 2008
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>VIA EDGAR</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">United States Securities and Exchange Commission<BR>
100 F Street, N.W.<BR>
Washington, D.C. 20549

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Re:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;Novogen Limited</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Novogen Limited (the &#147;Company&#148;) is in receipt of the comment letter, dated April&nbsp;11, 2008,
from the staff (the &#147;Staff&#148;) of the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) with
respect to the Company&#146;s Annual Report on Form 20-F for the fiscal year ended June&nbsp;30, 2007
(File No.&nbsp;0-29962).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company will submit its written response to the comments raised by the Staff in the
letter to the SEC via EDGAR no later than Friday, May&nbsp;16, 2008.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">NOVOGEN LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;/s/&nbsp;David Seaton
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">David Seaton&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="left" style="font-size: 8pt; margin-left: 3%; margin-top: 6pt"><B>Novogen Limited </B><FONT style="font-variant: SMALL-CAPS">abn</FONT> 37 063 259 754 140 Wick Road, North Ryde NSW 2113,Australia Telephone &#043;61 2 9878 0088 Facsimile &#043;61 2 9878 0055
</DIV>

<DIV align="left" style="font-size: 8pt; margin-left: 3%; margin-top: 0pt">nobogen@novogen.com www.novogen.com
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y57292cry5729201.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y57292cry5729201.gif
M1TE&.#EAQP!,`.8``+159Q%147-P;]5QBM872?GEZ>NIN<?'Q^>8J^NTP=:$
ME-JHL<HF5+DN5-F3I/_^_D]-3OSR](2#A+FZN-4D6=C9U_?5W<XW9/?=XL8B
M2_/,ULEG?>-RD,L92.CHY^(53!PG)W"1C-<<4"-/3ZFHINW4V<`V6YJ8E]=:
M=NO!R>6)GO3S\M0A2^)0>?[X^N['T)6PJ_;`S;I$8DMQ;/OL\/[\_.5:@\T=
M4OWU^,!9<[G*Q`@0$=-?@-1.=N'@W]%#:M\+1U])4-010\A!7"IH9?'P[]\A
M4O[Z^](N7<92;/S\_"4_/A1:5_KY^?[]_K"MJ\4P3HR)B<9,<-/2T%^"?.SM
MZ^[S\2)C7*2BH=UE@OCW]^0\:<C8T_K]_-P13OS^_LD12\+!P?S[^O?U]!]8
M5\_.S?[^_=WAWW]^?3HX-_G[^T=&1M!4<?W^_F1D9&Z#@5E96?W]_18_/]W=
MV[^^O3]`0-`M4=#2T9&0C_7Y]YZ=G7R@F:"@H><;5K.RL?___R'Y!```````
M+`````#'`$P```?_@'^"@X2%AH>(B8IFBHV.CY"1DI.4E9:7CCZ8FYR=GI^@
MFVBAI*6FIZB):7.IK:ZOL(X[8;&UMK>E<"%=N+V^OY!4,US`Q<;%(614:L?-
MSK![5TP3C,_6UZ![3$QD%=C?X)9[`>0S'G'AZ>J),$SD`2$>Z_/T[0'NRE7T
M^^$Z1-O;`E#)PZ^@-2[_W-UC0L6*P8?&/,P@0P[@E1`KJD'<:$M-,H7WR(R`
MX9"CR5C)*+X+(++AR9>M8-Q[%Y`,&1@P<YKB(FWE0FY<'N@\5J"$41I.'M'`
M@$$H)"=CBA@MX6$,.D%.!9V9L=)=0(9GAAIJ<PN!#!DF%-!XI(('#QR._QX<
ML8"``X<?)F3P4&$`PY$_6?\4>:.23,"95]Y`<E&@P!A%C&,80&`@1@$<23$]
M<%+CB(LC@14)?5"#K*0'H2%E[3*@@8D,)@QD5L3#A(D(C7"DV-``B1<O(BA0
MZ`#&M0(+<`>U(5$8Y+L1%4PG<K'@[()#$30L`&`""8/O#!JP,5#`!:4C-#0@
MR''V+``'!EX@3_W'3($7DE^\T,"_?W\:H45@P8!^/2(&#A&8]P=K-]S0`04M
M%.#(#QDPL%8B."@@0P8L&/%!'T,,`044&700G@P(!#;'"%T=%L`(5&BB2`$_
MB+!%"8;0,,!K'=Q@1!]]?.`%$"(T((4!"D+2A/\"W"%18@900LF`'3\,$$%J
M9B30``-]@&?'EV#:@80!-13R`EHFY("C(R4HD,-U@G#P@0@L".'%!F4FXD2-
M%%QHR`,EY,"A$5`HD`(--9"VP@M90-F!'0KD^8<3+-($T#LW-9+`!T#8,%M]
M+_S0@0A>4/"#`@ZDJJ$)#-R0P0`O..)$`0I<<(,(?1!J0@\H_$"!""((F<$"
M8AA2@P,,#)D!L$8TZZP1%!@06@(W$"#$#0/XF4@",C"@P"`<`#M$!EXPD,*G
MA3R`Q)RX&3(K&QD8P0`*,41@1F`U%&!`$BP0@(0"2:XAAT*7KC3"!'H.\`$+
M!A#B0@H7B'`#%#T88$'_!%]\<40$)>S+(10HQ)J(&"^@$*P(2+"A0@(:6("!
M!1I(ID`2&92@T2`/#.#@%@88D(#/":0JM`7H)D`!IT)0H`*ZABR`A!$<@$O!
M#1QDX:,,VA;B!`7`)5<(#2HL>X,-&N29FA@QF-#O#R+_0<<2,Q5<D1P2)%+`
M!7VP@0$A&OP`!A@9J%"@(2Y8T"@+#+R%R`,I),'U#2A8[$1J#Q2.0+N&*,!"
MX$P/XL3-@E`KA!`L>('$WHH@<'34@F31:@H%\&`$I)U/2@$!(G@]2`T)0`%L
M%A8\DL`/']P@0[M5+$$10`2_LX-TA-2`0+4._"5(`3G\QH`!NF.GPJB%)HDS
M_P9;!L<!YHF@AH@9`]@!A0J4))`!`1U`04`?68AOB`.D9C%(HR)XP0,,T*J:
M+0X)$NO>'R+``Q:(@`$:J%TA(J"`#@@A`PD831WDX!-R%$8.$V!:[`B0`0MD
M!0')`L,`](>("/2```0P0?"^ICF)66D39M`<%!`0/P80P`XJL(,7+M"V0_"/
M``,`EQWZD((%.@`,(L@!ZM*%P!NP,`$78`$+.%":]&6E!$,0`A`V<*$V@("#
M/J$(&NL`NC^\@`%":('U%O@#+Q"`#1*"A`'6U0$'A.8%4`#"!P:@._K$A7\L
M@-\DY!=#)R"`!50"$"(<0`$6?*MU'6JB$S!@`A$$[O\JA%"7B5C(@6HA(0;U
M@00.5.`%,"!!@'_X@AN4IY(.!@`$=S"$"@@`!6D-8@%P)$`*).4(&FS`"T(8
M0I(>$`$4C$H*,]R$$P;P(T5*P@`=N.,#,,`#$1!`!5D;!"6-8,TL5+*)?SB"
M"AC0@1],T7-38X#^]F3!'X2S$3$000<P6(T#U"$`1%@)&LEP!3G088)9^,`0
MIE@#G?E+@8IP@@%$(`0H3/$!,8!"CQS`0DLT\)N4P"8+_%>#&&1`"";(H!&!
MI<@'9$&+Z%P@#SK`@@$0TW8WD&<A<&`_)-ZTF,L*'"'>``*5@,0F+ZI#(7I'
M`#P-8@5)H)__)J$!)`C!#@O_<(H9'&"'&UQ``YXP@PWLP`(>3D*D&Q"$"[)`
M/RGDL1`.<&!+>7`#%L3T`6^<TYIV]RN=$H(&#*"3-2/Q`!-\(`-3%405X"`'
MP\BMH#LH1`7M2@@,7("$@X4$!M@@!",XX"HNT-P-LG#/2CAAK!GPXUEIFE9!
M6-:3#C"B7+$R4Q84\0$H_(`,WEF#NOIU$`7P80=0V08)'B()0(""#0I1@1VP
M2&XLD8,^U-H``DB!F!J@0$7A)`D*$@`(*E!0`=@*!@=`U+0M@((=V."`!;C7
MO7180`H><PAL=D`!9F"$$Q(`!B\TX)V".*(BG5#;(OZA`!M@P0UX@+DC]'6.
MKA5N_P+J8TA$(!<*B1T$'T;@6(48YD4Z8,0#@"F"2P[B!5R#`G<CX=T/*,!Z
M!4`!Z3CJB=/:KP,-:)!P&&`"KZZ8$`CH0`>RD%]!X*`''QARUN)*`+/68*8=
M,'`-4C`$`AC!EY,"%@-N"E@ZF5421Y!!<C,L""7@@98L><<5`H"3/S34JS$5
M!(H_H&)*1$`%0NA#]:XG8PKLF;"&/*T/RU57+=Y@:B;X\2""/-)"Q.!I&9`-
M(9C<L$DUT+:&P($#C`"$`>2Q!MYD`(33&5@6;,"XAP!L14U<"#>PB")74$EB
M5O"'$IA@R,4BA`60T`<[Q'82XR4`"QR0IQC33P'H$TT$]O]#`U!ZS@;SXUG/
M>H:`:B?@K85@=!*CIP+M_G<VE!;$D^MJ8,`4(0-TAE,-;I>!43NADR*00K(=
M$0,'06'"AZC"#$8@AQ&L>28@.,`?$M"C2O^U!]!B-20TD,5A929#+.A`#P"<
MOA(TH`$T+D0-;,``<E88$=HV1.P>R(.W'A'?3]9BN4-G!P+\P!M'\&:[#<&!
M.B$!K)%H`@*\D`$[X/P0<Z@#OUD":Q#0P0P`(,`%]CH(',A.Z1__$[588-'=
MQ=5$<6Y$=L&@``4>P0:0_+4DIF=)0YC!`GUU0&9.+H@C\&!./Y^@`I;E:1S<
M@.<_-<!E.\"!(]QK<5FQP`^`@,3_T@+F#!M<24'#8`$?(=M=#K@!$"#81K,+
M(@(#H.EM<&:!!CSHAH\H0;(>7P@7H*#GBG;$]^Y["#$@``H?V((%[J4`$1@!
MWZ:G7]Q#R4D";`^P>,\1#SZ&@<ICQ2DX"/('P)"`GQ;B#&?TX(O\X(`^=(#I
MA`CN!RBP@7DG(@8-'T!@7`"`^?T`WX[0@!$(0'I"'.'T6*5$V$!ZB`(@UPB7
M5,#Z4?D'%PP_`[M7".L40XWB>S_5!GJW.1L036:G7PE@`M;2`]YG"$JP!!Q$
M!$0P`@(@`P0P!,X7)\'2``LP.8[@`AN@75]E"!DE,5*@`<9'""GP`>RG0*;'
M(:G7"&$C_P*9M3L:H'DOX`2U1P#\YW\C@GV%@`'(Y2HEP@+.%P$.L"P,L`%%
ML#Y?\`<6<%D\EW6*4`9+H#S<$`09``8&=PBA,B?_%74CUDE>T'5M<#,XL`%W
M9SQ&:`B;4F(TV`)6=H.*H`(.]&7N,@!0T@,64'-&,(0-Q`!SB#,IX$-`(`0/
M\H$1L`'+(@(_P#V'L"0()`)0,$R2,`$@@($C$`0HA6W&PDB4R'^(<`0(T``1
M9T^(4`!2<"L=(`,O\(%RYDTJ<(="\`%^"`D<$"\[^%<;\%TVD$4LP'].9V4!
M.$%A\P&D@P2U\P`6,``,T"%(P`$O@`&-@0$=XSJ>-`3F-0E:@/\%2W`%5R"*
M`]`$C4`KR]).#H`!XO,`-)`"'(!`'3`$"V`VZ9("\-(C/X``R'$(9O`"U:("
M\X8#+;"+8A<)'-!QO:@U>P0$KA)Q0[@!$K.,H40#_$(G)E!AL[(!4`!)KL$&
M68`"*#`$#8`KLVB)E/`%`G`%H9@!L-0(%'1K.=4#")``,1`#/\,!MD(_)H``
M';4[+R")PL8`__@"-.`"G.$"C#$].DB#-M`!O.@"J$$Y3-.0(O"0A3!>K51H
MR*@`)O`#I(@(#W@B4?<P`X`62*"$-$4!1H`$68`!MN@(T$<&02`#=1D]:9-"
M-V`;)K`EPI%3P+.7:F4`0P!)#``%K@'_F'FQ)4Z2<81P9"=E`E(```"0`YJY
M`9S)F>@'+O/#E83@!`Q75S\T0TX@%1B0:[F1``C@`"GB"&;0!!BP`#W@)!<W
M!#R``"5@E9C0!JX&`0K7"-OD`!?`3COV'3>`!#R0`!.("#6``0XP+JW2(\31
M(X<&!3+0?(80`6Q073G6((<6'HXYG`UY9;+B`#0U.Q0W":0!>(?@!"X0`1@0
M`238"4E1!V[@`U%W"/FR``K``0J@`/)5!:,6";.2``/P`T@0)C]@`P0:`:SI
M,"HP`#;0`BU@`R:)`BVP!1ZZ!2WPD"JP!>CI"`7`!BS0!QE0ENYI2.KC1:10
M`150`R\H&O))_P,1@`-B4*./0!I+X1\M<QD/8'SRN(W:R!1(.B`#4I8%P!^&
M%ST6X%X.\)QB4:6:@1JH9J5:NJ5<VJ5>^J5@&J9B.J9D6J9F>J9HFJ9JNJ9L
MVJ9N^J9PZ@I%%J=?2@=X0`EAH(ZI,`<"APC39:450&M_X`&"6@@W0U^#\()*
M8'91(!CR()")(`&%:J@:,:>-8*E_H`D5@#"(H`=6>@`2X`8GD*D"(`%A<%`U
M<'1E("-Q,`%1@`8KX`%X@`8^0`=/@`9\(`A\,`I^H`<DH`1HH`=BX`-&YP%3
M(!1X\`1_L`)%0`)AH!$K,`'*^@<2<`":H`0>4`:#4`6,H`^Q.@@^4/^IA("I
MHR`(G'$(C5JE`D`+$J`%$/`'?'`"<!`'`K"?`D!?=(`&:@`'6!`&3^`!3R``
M</`'!W``>"!P:[`&`C"%;C,*:Y"J;J`%;G``3Z`'8;`#97`")#`($``!Z_H'
M<"```J`))``'>&`&($"K:0`':(`&`B!P)0L'9C`'"NL#?+`&:%`%H_H')%`&
M("``9H`%6H`'=?`$9H`&=>`-$E`&=9"N.8$&M(`&'@`"40`'?@`''I`&=:`'
M[RH(<W!T$G`"`C`!%9`&`G!0=$`'?%`&9E`':W`"55@$6#`*\QH&8SL!;1`'
M>G```A`'=%`W@H`&8V`&;O`'L!H&S\H(=?#_`&C0!J%JN`>E5/F%!DT``456
M!W&`!OD:N)E;']4*N(P@!A#@N&50!#S*#Y,;M5G[!'10!'A0JFC@!N4ZJ%,0
M!V$KJB>@!Q^+N!,@`5&`!6M``@^`!;-:-P*@!A,``21`#6(`M5CP!V$`N(8;
M!TJ@5)):L&'0LM9K!K[[!P?[!]8K`&LP!FPD"%0+`=$K"!+`O8(0!7X`N%I`
M`GBP!G\0!14@`-#S$F@@<%*[GU41!@'W!'7PO((P!5&P`A"0NS*RNV&`!;GT
M!\'[`!(0!^\+LF9`!Q-+`FI0!<ZZL>D;N"O@`]:[`H@K`7Y0!$HU"MVK!]I:
M!TXPLO>J5(`!!P5;\02`6S<W_`2`JP=8,`4C/`$",!1/X`TDL`)E(``GX`-C
ML`9%4`4"P`J"4`2ON@8L++L^\+($>P#YB@9:``<'Q0>A.@KH^[=Q``<G@`;]
MJJP?#+*Q>Z<24`0E3`+^1*W4VJ@L#+XU(`$>``=-L`:LT+;%<K1_H`4XK+X?
M'`6MJU3I.K!I^@!1,*V70+T%_*B"(,F!JP?I&@9*4`1%$`<GX*^9^@<3\!@K
MH(X(4Z_*:@9PX`9SP+0GT`35BP9^\`=S$,2S#+P4N\JVC`8ABZ85(`$D<`*3
?B@JSRPFGFTJ)VD9:P+!H6@9A\*>M<%!T.LVQ$`@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
